Tonix Pharmaceuticals is currently enrolling participants in a Phase 3 trial for posttraumatic stress disorder (PTSD). For more information, please visit www.recoverystudy.com or www.clinicaltrials.gov (NCT03841773).

News / Press Releases

: Press Releases

Press Releases

Tonix Pharmaceuticals to Present at the LD Micro Investor Conference

November 25, 2014 • 8:40 AM EST

Tonix Pharmaceuticals Reports Third Quarter 2014 Financial Results

November 10, 2014 • 8:40 AM EST

Tonix Pharmaceuticals Receives IND Clearance for TNX-201 in Episodic Tension-Type Headache

October 21, 2014 • 8:40 AM EDT

Tonix Pharmaceuticals Reports Top Line Results From Phase 2b BESTFIT Trial of TNX-102 SL in Patients With Fibromyalgia

September 29, 2014 • 6:00 AM EDT

Tonix Pharmaceuticals to Present at the BioCentury NewsMakers Conference

September 19, 2014 • 8:40 AM EDT

Tonix Pharmaceuticals to Present at the Rodman & Renshaw Global Investment Conference

September 3, 2014 • 8:40 AM EDT

Tonix Pharmaceuticals Announces Transfer to the NASDAQ Global Market

August 11, 2014 • 8:40 AM EDT

Tonix Pharmaceuticals Reports Second Quarter 2014 Financial Results

August 8, 2014 • 4:05 PM EDT

Tonix Pharmaceuticals to Present at Two Investor Conferences in August

August 6, 2014 • 8:40 AM EDT

Tonix Pharmaceuticals Announces Registered Direct Offering of $7.8 Million

July 11, 2014 • 8:20 AM EDT

Show All

News / Press Releases : Press Releases